-
公开(公告)号:US20210106595A1
公开(公告)日:2021-04-15
申请号:US16610191
申请日:2018-05-04
Applicant: Stichting VUmc
IPC: A61K31/395 , A61K31/4168 , A61K31/44 , A61K31/36 , A61K31/155 , A61K31/357 , A61P25/28
Abstract: The invention relates to Guanabenz or an analogue thereof for use in the treatment and to methods of treatment of a subject that has vanishing white matter (VWM), comprising administering the compound Guanabenz or an analogue thereof to the subject in need thereof. Also provided are methods with which the success of a medical intervention in a subject with VWM can be determined. Such methods comprise quantifying the translocation of Bergmann glia into the molecular layer in the cerebellum in a suitable sample of the subject. The sample is typically a post mortem sample.
-
公开(公告)号:US20240336698A1
公开(公告)日:2024-10-10
申请号:US18283547
申请日:2022-03-22
Applicant: Memorial Sloan Kettering Cancer Center , Sloan-Kettering Institute For Cancer Research , Memorial Hospital For Cancer and Allied Diseases , Stichting VUmc
Inventor: Maria Themeli , Michel Sadelain , Maria Sjöstrand , Afroditi Katsarou
IPC: C07K16/28 , A61K39/00 , A61P35/00 , C07K14/705 , C07K14/725
CPC classification number: C07K16/2896 , A61K39/4611 , A61K39/4631 , A61K39/464417 , A61K39/464426 , A61P35/00 , C07K14/7051 , C07K14/70521 , C07K16/2878 , A61K2239/13 , A61K2239/21 , A61K2239/28 , C07K2317/24 , C07K2317/622
Abstract: The presently disclosed subject matter provides uses of a chimeric costimulatory receptor (CCR) targeting CD38, and cells comprising a CD38 CCR and an antigen-recognizing receptor, and uses of such cells.
-
公开(公告)号:US11382920B2
公开(公告)日:2022-07-12
申请号:US16610191
申请日:2018-05-04
Applicant: Stichting VUmc
IPC: A61P25/28 , A61K31/395 , A61K31/155 , A61K31/357 , A61K31/36 , A61K31/4168 , A61K31/44
Abstract: The invention relates to Guanabenz or an analogue thereof for use in the treatment and to methods of treatment of a subject that has vanishing white matter (VWM), comprising administering the compound Guanabenz or an analogue thereof to the subject in need thereof. Also provided are methods with which the success of a medical intervention in a subject with VWM can be determined. Such methods comprise quantifying the translocation of Bergmann glia into the molecular layer in the cerebellum in a suitable sample of the subject. The sample is typically a post mortem sample.
-
14.
公开(公告)号:US20240101697A1
公开(公告)日:2024-03-28
申请号:US18208361
申请日:2023-06-12
Applicant: Janssen Biotech, Inc. , Stichting VUmc
Inventor: Homer Adams , Francois Gaudet , Niels Van de Donk , Kris Frerichs , Christie Verkleij
CPC classification number: C07K16/2896 , A61K45/06 , A61P35/00 , A61P35/02 , C07K16/2809 , C07K16/2878 , C07K16/30 , C07K16/468 , A61K2039/505 , C07K2317/21 , C07K2317/31
Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.
-
公开(公告)号:US20230340045A1
公开(公告)日:2023-10-26
申请号:US18186724
申请日:2023-03-20
Applicant: STICHTING VUMC
IPC: C07K14/47 , A61P35/00 , A61K39/00 , C07K14/245 , C07K14/78 , C07K16/18 , C12N15/62 , C12Q1/6886
CPC classification number: C07K14/4748 , A61P35/00 , A61K39/0011 , C07K14/245 , C07K14/78 , C07K16/18 , C12N15/62 , C12Q1/6886 , A61K2039/55566 , A61K2039/585 , A61K2039/6068 , C07K2319/21 , C07K2319/35 , C12Q2600/106 , C12Q2600/112
Abstract: The invention is in the field of medicine. More specifically, it is in the field of diagnosing tumor angiogenesis status and in the field of medical treatment of a subject who is suffering, suspected to suffer, or might suffer from a tumor in the future. In particular, the invention relates to a fusion polypeptide comprising a foreign antigen and a self antigen, wherein said foreign antigen consists of a polypeptide comprising an amino acid sequence of at least 12-15 amino acid residues, 12-24% of which residues are hydrophilic, bulky amino acid residues selected from the group consisting of histidine, glutamate, arginine, glutamine, aspartic acid and/or lysine.
-
公开(公告)号:US20220280487A1
公开(公告)日:2022-09-08
申请号:US17638086
申请日:2020-08-26
Applicant: Stichting VUmc , Stichting VU
Inventor: Eelco RUIJTER , Mark Karsten RONG , Alexander SPEER , Wilhelmus BITTER , Stewart Thomas COLE
IPC: A61K31/433 , A61P31/06
Abstract: The invention relates to compounds and pharmaceutically acceptable salts thereof, and to their medical use. Exemplary medical uses are the prevention and treatment of a bacterial infection, for example, a mycobacterial infection, such as a Mycobacterium tuberculosis infection, e.g., in a respiratory system and/or extrapulmonic. The invention further relates to a use of such compounds, pharmaceutically acceptable salts thereof or prodrugs of the compounds as chemotherapeutic agents. Also, the invention relates to a use of such compounds, pharmaceutically acceptable salts thereof or prodrugs of the compounds for inhibiting mycobacterial type VII secretion.
The compounds have the following formula wherein Q and X are, respectively, CH and C, CR2 and C, CH and N, CR2 and N, or N and C; R1 is hydrogen, halide or optionally substituted linear or branched alkoxy having 1 or 2 carbon atoms; R2 is independently selected from hydrogen, halide or optionally substituted linear or branched alkoxy having 1 or 2 carbon atoms, and R3 is optionally substituted linear or branched alkoxy having 1-6 carbon atoms, haloalkyl having 1-6 carbon atoms, n-propyl, 2-propenyl, 2-propynyl, or n-pentyl, or a pharmaceutically acceptable salt of the compound, for use in the prevention or treatment of a bacterial infection.-
公开(公告)号:US20190160147A1
公开(公告)日:2019-05-30
申请号:US16095273
申请日:2017-04-21
Applicant: Stichting VUmc
Inventor: Walter Joseph Paulus
IPC: A61K38/17 , A61K31/121
Abstract: The treatment of diastolic dysfunction in a subject and, in particular, compositions for use and methods in treating diastolic dysfunction are disclosed. In one aspect, the disclosure provides a composition for use comprising a therapeutically effective amount of a substance that increases the level and/or activity of a crystalline protein in cardiomyocytes of the subject. In particular, the composition for use according to the disclosure comprises a therapeutically effective amount of the alpha B crystalline protein. It was found that the composition for use is capable of treating diastolic dysfunction and diastolic heart disease in subjects with failing hearts that have a higher cardiomyocyte stiffness than controls. Particularly, addition of alpha B crystalline reduced the higher stiffness of failing cardiomyocytes to the level observed in control cardiomyocytes.
-
18.
公开(公告)号:US20190082953A1
公开(公告)日:2019-03-21
申请号:US16127377
申请日:2018-09-11
Applicant: Stichting VUmc
Abstract: A Method of evaluating a correspondence between a target surface and a reconstructed surface representing the target surface is includes constructing the reconstructed surface by processing information obtained by illuminating the target surface with a pattern of light of a stimulator source, and capturing a reflected image of the pattern of light on an image target. The method further includes the steps of: determining a reference image point on the image target corresponding to a reference stimulator point on the stimulator source; calculating for the reference image point, using the reconstructed surface; a residual representing the correspondence between the target surface and the reconstructed surface; and displaying the residual together with the reflected image.
-
19.
公开(公告)号:US20190029511A1
公开(公告)日:2019-01-31
申请号:US16070042
申请日:2017-01-11
Applicant: Stichting VUmc
Inventor: Bob Wilhelm van Dijk
Abstract: A method, system and computer readable medium for determining a strabismus angle of the eyes of an individual by: positioning the individual with his or her eyes in front of an eye tracker device and in front of a screen at a viewing distance; displaying a small image element on the screen; measuring a position and line of sight of the eyes of the individual with the eye tracker device while the individual is focussing on the small image element; forwarding the measured position and line of sight of the eyes from the eye tracker device to a computer system; and, calculating the strabismus angle between the eyes by calculating the difference in line of sight of the left and right eyes of the individual.
-
公开(公告)号:US20180021385A1
公开(公告)日:2018-01-25
申请号:US15548666
申请日:2015-12-22
Applicant: Stichting VUmc , A-Skin Holding B.V.
Inventor: Susan GIBBS , Riekeld Johannes SCHEPER
CPC classification number: A61K35/36 , A61K35/33 , C12N5/0629 , C12N5/0656 , C12N2502/094 , C12N2502/1323
Abstract: The present disclosure relates to a method for producing a composition, wherein the method comprises the steps of co-culturing immortalized fibroblasts and immortalized keratinocytes, thereby producing secretion; separating the secretion from the fibroblasts and keratinocytes; and providing a pharmaceutically acceptable composition comprising the secretion. The present disclosure also relates to the composition obtainable by the method, wherein the composition preferably is a pharmaceutical composition for medical use, preferably for use in the treatment of a wound, preferably a chronic or acute wound.
-
-
-
-
-
-
-
-
-